Myeloid Therapeutics — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
CRT-402Patients with refractory autoimmune diseases often have limited treatment options and ongoing disease activity despite standard therapies. CRT-402 is an in vivo Cluster of differentiation 19 (CD19)-targeted CAR-T cell therapy designed to deplete CD19-positive B cells and promote immune system reset. This study evaluates the safety, tolerability, preliminary efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of CRT-402 in participants with active refractory systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM).	Lupus	Phase 1/2	Immunomodulation + Thérapie cellulaire	Australia	À vérifier
CRT-402Patients with refractory autoimmune diseases often have limited treatment options and ongoing disease activity despite standard therapies. CRT-402 is an in vivo Cluster of differentiation 19 (CD19)-targeted CAR-T cell therapy designed to deplete CD19-positive B cells and promote immune system reset. This study evaluates the safety, tolerability, preliminary efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of CRT-402 in participants with active refractory systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM).	Lupus	Phase 1/2	Immunomodulation + Thérapie cellulaire	Australia	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
CRT-402	Lupus	Phase 1/2	NCT07778446	A Study to Test CRT-402 in Refractory Autoimmune Disease	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.